Seres Therapeutics, Inc.

Axcella Health Inc.

Flagship Pioneering Innovations V, Inc.

Bayer Healthcare LLC

Rubius Therapeutics, Inc.

Evelo Biosciences, Inc.

Joule Unlimited Technologies, Inc.

T2 Biosystems, Inc.

Seres Health, Inc.

Pronutria, Inc.

Joule Unlimited, Inc.

Massachusetts Institute of Technology

Genomatica, Inc.

Reg Life Sciences, LLC

Ls9, Inc.

David Arthur Berry

Geoffrey Von Maltzahn

Noubar Boghos Afeyan

David N Cook

Matthew R Henn

John Grant Aunins

Kevin Daniel Litcofsky

Anthony Mario D'Onofrio

Michael Hamill

Mary-Jane Lombardo McKenzie

Nathaniel Silver

Brett Adam Boghigian

Brian Goodman

Gregory McKenzie

Marin Vulic

Shaila Rahman

Toshiro Kendrick Ohsumi

Jonathan Winkler

Dan Eric Robertson

Frank Anthony Skraly

Avak Kahvejian

Jordi Mata-Fink

Christian Perry Ridley

Johanne Kaplan

John Round

Rajeev Chillakuru

John Kramarczyk

Martha Sholl

Kevin P Cowan

Michael A Spohn

John Patrick Casey, Jr

Spencer Cory Peck

Han Zhang

Steven John Taylor

Mary-Jane Lombardo Mckenzie

Barry Tucker

Brian D Green

Sriram Kosuri

Timothy F Briggs

Kathleen Nudel

Bernard Lanter

Laura Gabriela Lande

Mi-Jeong Kim

Koji Yasuda

Leonard Buckbinder

Cheri Snedeker

Jessica Alexander

Anna Liang

Dinara Gunasekera

John Robert Proudfoot

Nikos Basil Reppas

Chung-Wei Lee

Ferdinand Edward Massari

Subhayu Basu

Ying-Ja Chen

Regina Wilpiszeski

David Young

Jenny Liu

George M Church

Arthur E Uber, Iii

Jay D Keasling

James Albert Dedig

Andreas W Schirmer

W David Lee

Zhihao Hu

Stephen B Del Cardayre

Keith Lipford

Shane A Brubaker

Phillip Samayoa

Raymond C Hoffman

Martin J Uram

Raffi Afeyan

Douglas Descalzi

Neal Gordon

Michael Doherty

Lisa C Friedman

Harry Luithardt

Angela She

Ram Sasisekharan

Douglas Adam Levinson

Michael Donald McDermott

Mariano Mumpower

Thomas Jay Lowery, Jr

Christopher David Capone

Shiladitya Sengupta

Benjamin Thomas Krupp

Eric Devroe

Tuan A Elstrom

Jessie Delgado

Mark John Audeh

David V Erbe

Patrick Campbell

Chet B Larrow

James Fentress

Martin J Gibler

Vince Delbrugge

Aarthi Chandrasekaran

Brian Cain

Kristine Holley

Adam Steege

Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Synergistic bacterial compositions and methods of production and use thereof

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Acylated active agents and methods of their use for the treatment of autoimmune disorders

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

An injector system for delivering a medical fluid, the injector system including an injector configured to receive at least one syringe, the injector comprising at least one piston for releasably engaging and reciprocally driving a plunger or an end wall of the at least one syringe; and a syringe retaining interface comprising one or more retaining elements configured to engage at least a portion of a distal end portion of the at least one syringe to limit movement of the at least one syringe in a distal direction relative to the injector as the medical fluid is delivered from the reservoir via distal movement of the at least one piston.

Syringe retention feature for fluid injector system

A fluid container having a proximal end having an end wall, a distal end having an open-ended neck, and a sidewall extending between the proximal end and the distal end along a longitudinal axis is described. A localized crystallinity of a polymeric material of the fluid container of at least a first region of the fluid container is greater than a crystallinity of a polymeric material of the fluid container of at least a second region. Examples of fluid containers include medical fluid containers, such as medical bottles and syringes, including rolling diaphragm-type syringes, and commercial beverage containers Articles of manufacturer formed form a polymeric material and having regions with increased localized polymeric crystallinity are also described.

Fluid-container and method for controlling crystallinity in blow-molded container

Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.

Conjugates and methods of using the same

The present disclosure described herein provides compositions with a membrane-penetrating properties and methods for allowing translocation across a membrane without disruption.

Compositions and methods for cell delivery

A fluid control valve for use in a fluid delivery system for delivering fluid to a patient includes a valve body defining an internal chamber, a first inlet port for receiving a first inlet tube, a second inlet port for receiving a second inlet tube, an outlet port, and a sliding valve member slidably disposed in the internal chamber. The first inlet tube defines a first inlet lumen axially aligned with the internal chamber. The second inlet tube defines a second inlet lumen axially aligned with the internal chamber. The sliding valve member includes a first sealing end and second sealing end. The sliding valve member is positionable in a first operating state, a second operating state, and a third operating state based on a flow differential between the first inlet lumen and the second inlet lumen.

Fluid control valve and manifold

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome

Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.

Network-based microbial compositions and methods

The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

Methods and compositions for modulating gene expression

Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Probiotic compositions containing clostridiales for inhibiting inflammation

Growing community of inventors

Brookline, MA, United States of America

David Arthur Berry